EXAS Exact Sciences
- 60.540
- +0.530+0.88%
- 61.200
- +0.660+1.09%
Exact Sciences News
Buy Rating Affirmed for Exact Sciences on Promising Multi-Cancer Detection Technology
Exact Sciences Analyst Ratings
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Geron (GERN)
Buy Rating Affirmed for Exact Sciences Amid Market Expansion and Product Advancement Prospects
Analysts Offer Insights on Healthcare Companies: Neurocrine (NBIX), Arcellx Inc (ACLX) and Exact Sciences (EXAS)
Exact Sciences (EXAS) Receives a Buy From BTIG
Analysts Offer Insights on Healthcare Companies: Align Tech (ALGN), Exact Sciences (EXAS) and Springworks Therapeutics (SWTX)
Analysts' Opinions Are Mixed on These Healthcare Stocks: Exact Sciences (EXAS), United Therapeutics (UTHR) and Ionis Pharmaceuticals (IONS)
Canaccord Genuity Maintains Buy on Exact Sciences, Lowers Price Target to $90
Exact Sciences Analyst Ratings
Piper Sandler Sticks to Their Buy Rating for Exact Sciences (EXAS)
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Denali Therapeutics (DNLI) and Treace Medical Concepts (TMCI)
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS) and Tandem Diabetes Care (TNDM)
Craig-Hallum Reaffirms Their Buy Rating on Exact Sciences (EXAS)
Analysts Offer Insights on Healthcare Companies: Exact Sciences (EXAS), Alnylam Pharma (ALNY) and Catalent (CTLT)
Craig-Hallum Reaffirms Their Buy Rating on Exact Sciences (EXAS)
Analysts Are Bullish on These Healthcare Stocks: Intellia Therapeutics (NTLA), Exact Sciences (EXAS)
Buy Rating for Exact Sciences: Strong Q4 Sales and Positive 2024 Outlook Drive Analyst Confidence
Exact Sciences (EXAS) Receives a Buy From BTIG
Benchmark Upgrades Exact Sciences to Buy, Announces $91 Price Target
Analysis
Price Target
No Data
